Medicare to Expand GLP-1 Coverage for Weight Loss via 2026 Bridge Program

Medicare is set to expand access to GLP-1 weight-loss medications through the introduction of a 'bridge program' scheduled for launch in July 2026. This initiative will allow seniors enrolled in Medicare Part D or Medicare Advantage plans to receive these medications for weight loss, provided their physician submits a prior authorization request. Currently, Medicare coverage for GLP-1 drugs is largely restricted to the treatment of specific medical conditions, such as Type 2 diabetes. For beneficiaries seeking these drugs for weight management, out-of-pocket costs have remained a significant barrier, often exceeding $1,000 per month. The bridge program serves as a transitional phase. Beginning in 2027, the authority to cover GLP-1s for weight loss will move to individual Part D plan providers. This means that the availability of these drugs will vary by plan, requiring beneficiaries to carefully compare options during the Open Enrollment Period to ensure continued access. From a market perspective, this regulatory shift potentially expands the addressable patient population for GLP-1 manufacturers. However, the eventual shift to private plan discretion in 2027 introduces a layer of uncertainty regarding long-term reimbursement rates and widespread adoption across all Medicare tiers.